Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study

Summary

A Phase 2, Open-Label Extension study to evaluate the long-term safety and tolerability of daxdilimab in participants with Systemic Lupus Erythematosus completing the treatment period of the RECAST SLE clinical study.

Timeline

Start

2022-06-01

Primary completion

2023-10-31

Completion

2023-10-31

Outcome

Outcome not reported

Stopped (Business): “Sponsor Decision”

Drugs

Indications